News
Researchers working at with Seoul National University together with GPCR Therapeutics Inc. have focused on targeting pairs of G protein-coupled receptors (GPCRs) starting with the CXC chemokine ...
GPCR Therapeutics has secured target patents around prominent GPCRs such as CXCR4 and possesses multiple pipelines addressing blood cancers and solid tumors, genetic disorders, idiopathic ...
SEOUL, Korea and REDWOOD CITY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage, international biopharmaceutical company, announced today the expansion of its ...
The agreement includes the acquisition of GPCR USA, a subsidiary of GPCR Therapeutics, along with technology transfer for the company's CXCR4 inhibitor, which is currently in Phase 2 clinical ...
SEOUL, Korea and REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage international biopharmaceutical company, announces it enters into an out ...
CHICAGO--(BUSINESS WIRE)-- Exicure, Inc. (XCUR) (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc ...
SEOUL, Korea and REDWOOD CITY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage, international biopharmaceutical company, announced today the expansion of its ...
GPCR Therapeutics, Inc. is developing a diverse pipeline targeting both CXCR4, one of the most prevalent chemokine GPCRs overexpressed in more than 23 cancers, and other GPCRs that promote or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results